Terms: = Lymphoma AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Treatment
26110 results:
1.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract] [Full Text] [Related]
2. [UPLC-QE-Orbitrap-MS combined with network pharmacology to explore differential components and mechanisms of raw and scorched rhubarb for treatment of ulcerative colitis].
Sun J; Xu WJ; Zhong LY; Chen JB; Dong L
Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(7):1834-1847. PubMed ID: 38812196
[TBL] [Abstract] [Full Text] [Related]
3. A retrospective analysis of the incidence and risk factors of perioperative urinary tract infections after total hysterectomy.
Cao X; Tu Y; Zheng X; Xu G; Wen Q; Li P; Chen C; Yang Q; Wang J; Li X; Yu F
BMC Womens Health; 2024 May; 24(1):311. PubMed ID: 38811924
[TBL] [Abstract] [Full Text] [Related]
4. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
[TBL] [Abstract] [Full Text] [Related]
5. Phase 1 Study of CK0801 in treatment of Bone Marrow Failure Syndromes.
Kadia TM; Huang M; Pemmaraju N; Abbas HA; Ly C; Masarova L; Yilmaz M; Lyu MA; Zeng K; Sadeghi T; Cook R; DiNardo CD; Daver N; Issa GC; Jabbour E; Borthakur G; Jain N; Garcia-Manero G; Parmar S; Flowers C; Kantarjian H; Verstovsek S
NEJM Evid; 2024 Jun; 3(6):EVIDoa2300362. PubMed ID: 38804782
[TBL] [Abstract] [Full Text] [Related]
6. Predictive Factors of Therapy-Related Cardiovascular Events in Patients with lymphoma Receiving Anthracyclines.
Lopez-Garcia A; Macia E; Gomez-Talavera S; Castillo E; Morillo D; Tuñon J; Ibañez B; Cordoba R
Med Sci (Basel); 2024 Apr; 12(2):. PubMed ID: 38804379
[TBL] [Abstract] [Full Text] [Related]
7. [Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen].
Hou SM; Shao JB; Li H; Zhang N; Zhu JS; Wang D; Fu P
Zhongguo Dang Dai Er Ke Za Zhi; 2024 May; 26(5):469-475. PubMed ID: 38802906
[TBL] [Abstract] [Full Text] [Related]
8. Consolidation therapy with autologous stem cell transplantation after remission of induction chemotherapy prolongs the survival of patients with peripheral T-cell lymphoma.
Fulati W; Ma J; Wu M; Qian W; Chen P; Hu Y; Chen M; Xu Y; Huang Z; Zhang H; Xie Y; Shen L
Front Immunol; 2024; 15():1382189. PubMed ID: 38799461
[TBL] [Abstract] [Full Text] [Related]
9. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J; Bachy E; Morschhauser F; Cartron G; Fukuhara N; Daguindau N; Casasnovas RO; Snauwaert S; Gressin R; Fox CP; d'Amore FA; Staber PB; Tournilhac O; Bouabdallah K; Thieblemont C; André M; Rai S; Ennishi D; Gkasiamis A; Nishio M; Fornecker LM; Delfau-Larue MH; Sako N; Mule S; de Leval L; Gaulard P; Tsukasaki K; Lemonnier F
Lancet Haematol; 2024 Jun; 11(6):e406-e414. PubMed ID: 38796193
[TBL] [Abstract] [Full Text] [Related]
10. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S; Ozturk A; Karadurmus N; Korkmaz T; Yumuk PF; Cicin I; Paydas S; Cilbir E; Sakalar T; Uysal M; Yesil Cinkir H; Uskent N; Demir N; Sakin A; Dursun OU; Aver B; Turhal NS; Keskin S; Tural D; Eralp Y; Bugdayci Basal F; Yasar HA; Sendur MAN; Demirci U; Cubukcu E; Karaagac M; Cakar B; Tatli AM; Yetisyigit T; Urvay S; Gursoy P; Oyan B; Turna ZH; Isikdogan A; Olmez OF; Yazici O; Cabuk D; Seker MM; Unal OU; Meydan N; Okutur SK; Tunali D; Erman M;
Medicine (Baltimore); 2024 May; 103(21):e37972. PubMed ID: 38787994
[TBL] [Abstract] [Full Text] [Related]
11. Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland: A case report and literature review.
Zhong Q; Yan Y; Li S
Medicine (Baltimore); 2024 May; 103(21):e38303. PubMed ID: 38787969
[TBL] [Abstract] [Full Text] [Related]
12. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract] [Full Text] [Related]
13. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Javidi-Sharifi N; Brown JR
Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
[TBL] [Abstract] [Full Text] [Related]
14. FAT1 inhibits the proliferation of DLBCL cells via increasing the m
Wang TL; Miao XJ; Shuai YR; Sun HP; Wang X; Yang M; Zhang N
Sci Rep; 2024 May; 14(1):11836. PubMed ID: 38782965
[TBL] [Abstract] [Full Text] [Related]
15. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Salem AH; Menon RM
Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
[TBL] [Abstract] [Full Text] [Related]
16. Observation of lymphadenopathy, systemic symptoms, and treatment in suspected indolent cutaneous B-cell lymphomas.
Puccio J; Huang Y; Viveiros MD; Reneau JC; Chung C; Spaccarelli N; Dulmage B
Arch Dermatol Res; 2024 May; 316(5):199. PubMed ID: 38775835
[TBL] [Abstract] [Full Text] [Related]
17. Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O; Thörn E; Osterman P; Fors M; Dernstedt A; Forsell MNE; Erlanson M; Landfors M; Degerman S; Hultdin M
Clin Epigenetics; 2024 May; 16(1):68. PubMed ID: 38773655
[TBL] [Abstract] [Full Text] [Related]
18. Thyroid papillary carcinoma combined with primary follicular lymphoma: a case report.
Xu T; Wu L; Ye H; Luo S; Wang J
Diagn Pathol; 2024 May; 19(1):69. PubMed ID: 38773600
[TBL] [Abstract] [Full Text] [Related]
19. Surgical outcomes of robotic thyroidectomy for thyroid tumors over 4 cm via the bilateral axillo-breast approach.
Bae HL; Wong JS; Kim SJ; Jung Y; Choi JB; Kwak J; Yu HW; Chai YJ; Choi JY; Lee KE
Sci Rep; 2024 May; 14(1):11646. PubMed ID: 38773181
[TBL] [Abstract] [Full Text] [Related]
20. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Clin Exp Med; 2024 May; 24(1):105. PubMed ID: 38771501
[TBL] [Abstract] [Full Text] [Related]
[Next]
